作者
Faryal Altaf,Eeshal Fatima,Mikail Khanzada,Adnan Safi,Zaheer Ahmad Qureshi
摘要
Introduction: Gastric cancer is the 5th most common cancer worldwide. The majority of patients are diagnosed at advanced stages when relying just on surgery may not be adequate because, despite surgical resection, the prognosis remains poor, and most patients relapse after surgery. Immune checkpoint inhibitors such as anti-programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) antibodies are primarily approved for the treatment of inoperable or metastatic solid cancers. Sintilimab is a highly selective monoclonal anti-PD-1/PD-L1 antibody with a robust anti-tumor response. The primary aim of this study is to assess the efficacy and safety of sintilimab in gastric or gastro-esophageal junction cancer. Methods: A thorough search was conducted on PubMed, Scopus, and Google Scholar from inception till May 2024. OpenMeta[Analyst] was used to perform statistical analysis. The pooled disease control rate, objective response rate, stable disease rate, and partial disease rate with 95% confidence interval (CI) were assessed using the random-effects model. Heterogeneity was evaluated using the Higgins I2 index. In all cases, P-value < 0.05 was indicative of significant results. This review has been registered with PROSPERO (CRD42024521560). Results: A total of 16 studies, consisting of 932 patients who received sintilimab therapy, were included in our study (Table 1). The majority of the patients (649) were male. The mean age of the participants ranged from 21 to 86 years. The pooled proportion revealed a disease control rate of 73% (95% CI = 66.2% - 79.3%; P-value < 0.001), an objective response rate of 40% (95% CI = 24.3% - 57.2%; P-value < 0.001), and a stable disease rate of 34.6% (95% CI = 22.8% - 47.4%; P-value < 0.001), and a partial disease rate of 31.6% (95% CI = 18.1% - 45.1%; P-value < 0.001). However, high heterogeneity was observed. Commonly reported adverse events included anemia, neutropenia, vomiting, and an increase in the levels of liver enzymes, but none of these adverse events showed a significant association with sintilimab therapy. Conclusion: Sintilimab shows promising efficacy and a well-tolerated safety profile. Our results suggest its potential as an innovative therapeutic option for individuals with gastric or gastro-esophageal junction cancer; however, significant heterogeneity was observed in some results, making it difficult to come to a solid conclusion. Therefore, large-scale randomized trials are required to confirm our findings. Table 1. - Characteristics of the included studies Study Name Year Type of Study Participants (n) Age (years)* Intervention Jiang et al. 2022 Single-arm Phase 2 Study 36 65.5 (43-76) Sintilimab + Oxaliplatin + Capecitabine Xu et al. 2023 Phase 3 RCT 327 62 (55-67) Sintilimab + Chemotherapy (Capecitabine + Oxaliplatin) Wei et al. 2023 Single-arm Phase 2 Trial 34 65.5 (58-68) Sintilimab + Chemoradiotherapy (nab-paclitaxel) Ding et al. 2022 Prospective Study 30 62 (30-75) Sintilimab + XELOX Chemotherapy Zhang et al. 2023 Single-arm Phase 2 Trial 30 59 (28-73) Sintilimab + Apatinib + Chemotherapy (Irinotecan + Paclitaxel) Wang et al. 2022 Single-center Retrospective Study 39 64 (41-78) Sintilimab + Chemotherapy (nab-paclitaxel) Jiang et al. 2020 Open label Phase 1b study 20 59.8 (36.9-69.3) Sintilimab + Chemotherapy (Capecitabine + Oxaliplatin) Wang et al. 2021 Retrospective Study 37 62 (21-86) Sintilimab Li et al. 2024 Prospective Cohort Study 32 58 (43-70) Sintilimab + Chemotherapy (FLOT) Hou et al. 2023 Retrospective Study 52 64 (30–77) Sintilimab + apatinib oral Nie et al. 2021 Retrospective Study 52 64 (30–80) Sintilimab + chemotherapy (apatinib, trastuzumab, or nab-paclitaxel) Guo et al. 2022 Single-arm Phase 2 Trial 30 62 (30–72) Sintilimab + XELOX regimen Gao et al. 2023 Retrospective Study 34 61 (39–73) Sintilimab (combined with apatinib) Huang et al. 2023 Retrospective Study 75 64 (31–75) Sintilimab Huang et al. 2022 Retrospective Study 48 59 (28-81) Sintilimab combined with chemotherapy Zhou et al. 2023 Single-arm Phase 2 Trial 56 18-75** Sintilimab and nabpaclitaxel